Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value
Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma
Last night Gilead execs basked in the glow of market-bending sales numbers, backed by the continuing megasuccess of its two hep C drugs, Harvoni and Sovaldi, which racked up close to $5 billion in revenue for the second quarter. So naturally analysts want to know how they plan to spend the cash.
Venture investor Foresite Capital closed a $450 million new fund, its largest ever, and is setting out to find the next generation of promising drug developers.
Foresite Capital Closes $450 Million Fund III to Finance Transformative, Late-stage Healthcare Companies
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.